Skip to main content
SpringerLink
Log in

Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?

  • Letter to the editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241–52.

    Article  PubMed  CAS  Google Scholar 

  2. Skehan SJ, Brown AL, Thompson M, Young JE, Coates G, Nahmias C. Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics 2000;20:713–23.

    PubMed  CAS  Google Scholar 

  3. Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202–10.

    PubMed  CAS  Google Scholar 

  4. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol 2005;6:864–70.

    Article  PubMed  Google Scholar 

  5. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6:659–68.

    Article  PubMed  Google Scholar 

  6. Duong CP, Hicks RJ, Weih L, Drummond E, Leong T, Michael M, et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging 2006;33:770–8.

    Article  PubMed  Google Scholar 

  7. Duong CP, Demitriou H, Weih L, Thompson A, Williams D, Thomas RJ, et al. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging 2006;33:759–69.

    Article  PubMed  Google Scholar 

  8. Bombardieri E. The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment. Eur J Nucl Med Mol Imaging 2006;33:753–8.

    Article  PubMed  Google Scholar 

  9. Rampin L, Nanni C, Fanti S, Rubello D. Value of PET-CT fusion imaging in avoiding potential pitfalls in the interpretation of 18F-FDG accumulation in the distal oesophagus. Eur J Nucl Med Mol Imaging 2005;32:990–2.

    Article  PubMed  Google Scholar 

  10. Bar-Shalom R, Guralnik L, Tsalic M, Leiderman M, Frenkel A, Gaitini D, et al. The additional value of PET/CT over PET in FDG imaging of esophageal cancer. Eur J Nucl Med Mol Imaging 2005;32:918–24.

    Article  PubMed  Google Scholar 

  11. Leong T, Everitt C, Yuen K, Condron S, Hui A, Ngan SY, et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol 2006;78:254–61.

    Article  PubMed  Google Scholar 

  12. Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N, et al. Is there a role for FDG-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 2004;73:269–75.

    Article  PubMed  Google Scholar 

  13. Hustinx R, Eck SL, Alavi A. Potential applications of PET imaging in developing novel cancer therapies. J Nucl Med 1999;40:995–1002.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, Hospital of University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA

    Sandip Basu & Abass Alavi

Authors
  1. Sandip Basu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abass Alavi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abass Alavi.

Additional information

This work was supported in part by the International Union against Cancer (UICC), Geneva, Switzerland, under the ACSBI fellowship.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basu, S., Alavi, A. Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?. Eur J Nucl Med Mol Imaging 34, 604–605 (2007). https://doi.org/10.1007/s00259-006-0315-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-006-0315-z

Keywords

Search

Navigation